Stacy Price
Directeur Technique/Scientifique/R&D chez INVIVYD, INC.
Fortune : - $ au 30/04/2024
Profil
Stacy Price is currently the Chief Technology & Manufacturing Officer at Invivyd, Inc. Prior to this role, Stacy held positions as the Senior Vice President-Technical Operations at Alaunos Therapeutics, Inc. and Chief Technical Officer at Akouos, Inc. Stacy has also received undergraduate and graduate degrees from Tufts University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INVIVYD, INC.
-.--% | 18/12/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Stacy Price
| Sociétés | Poste | Début |
|---|---|---|
| INVIVYD, INC. | Directeur Technique/Scientifique/R&D | 01/03/2023 |
Anciens postes connus de Stacy Price
| Sociétés | Poste | Fin |
|---|---|---|
| AKOUOS | Directeur Technique/Scientifique/R&D | - |
| ALAUNOS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Stacy Price
| Tufts University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Akouos, Inc.
 Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
